Prostate cancer patients undergoing radical prostatectomy increased by double digits while those undergoing brachytherapy decreased.
New data confirms that ConfirmMDx, an epigenetic assay, is able to accurately identify prostate cancer aggressiveness
Testosterone replacement therapy (TRT) may promote prostate cancer tumor growth.
Findings suggest that normalization of blood fats may reduce risk of prostate cancer.
Mortality was greater with external beam radiotherapy across treatment-specific nomograms for predicting biochemical recurrence.
Researchers confident in this approach because candidates for active surveillance are a heavily screened population.
A biomarker present on the KLK3 gene can predict which GS7 prostate cancer patients will be more aggressive.
Growth in robot-assisted radical prostatectomy (RARP) use especially pronounced among surgeons at urban hospitals.
Meta-analysis shows that the risk is increased 20% with each 20 cigarettes smoked per day.
Urologic complications requiring hospital admission grew from 3.6% in 2000 to 3.9% in 2008, largely because of infections.
Outcomes of robot-assisted radical prostatectomy in obese patients are mostly comparable to non-obese patients.
Men who had PSA relapse after receiving post-radical surgery salvage radiation therapy had a median overall survival of nearly 14 years.
Radiotherapy given within 6 months of radical prostatectomy reduces cancer-specific mortality in men with highly aggressive disease.
High rates of preserved sexual function with combination beam plus brachytherapy.
Utilization rates jumped by double digits across prostate cancer risk groups from 2004 to 2011.
Men with male pattern baldness may face a higher risk of aggressive prostate cancer.